Changes in the product label for pimozide illustrate both the promises and the challenges of personalized medicine.
Department of Psychiatry and Behavioral Health and Kansas University, Wichita Clinical Trial Unit, Kansas University School of Medicine, 8911 E Orme, Wichita, KS 67207, USA.
Sheldon H
SH
Preskorn
D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D018492:Dopamine Antagonists / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D006801:Humans; D008133:Long QT Syndrome / Q000517:prevention & control*; D010868:Pimozide / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D011110:Polymorphism, Genetic; D057285:Precision Medicine; D005879:Tourette Syndrome / Q000188:drug therapy* / Q000235:genetics*
D018492:Dopamine Antagonists; D010868:Pimozide; D019389:Cytochrome P-450 CYP2D6